Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2012

View Archived Issues

Kythera launches pivotal ATX-101 program

NINA device-coupled RT-LAMP assay allows point-of-care HIV-1 detection

Takeda patents novel antipsychotic drugs

New therapeutics for vascular disease designed in India

Novel antibacterials developed in Israel

ImmunoGen reports new HER3-binding immunotherapies

Bristol-Myers Squibb divulges new products to treat HIV infection

Boston Scientific announces new product launch in Japan

Mitsubishi Tanabe and Daiichi Sankyo enter strategic alliance

FDA accepts NDA resubmitted by Eisai

Phase II AMG-853 trial does not meet primary endpoint

Pre-IND meeting scheduled for influenza drug

Concert Pharmaceuticals enters new collaboation

Canadian study reveals new potential tool for prostate cancer diagnosis

Savient launches named-patient program for gout therapy

Anticancer drugs are possible treatments for lethal Ebola virus infections

Acadia Pharmaceuticals and Allergan extend drug discovery collaboration

Zalicus completes trial of reformulated N-type calcium channel blocker

BioLineRx clear to begin study of BL-7040

FDA issues complete response letter for ezetimibe/atorvastatin tablets

Anthera Pharmaceuticals to continue blisibimod study as planned

MorphoSys completes enrollment in rheumatoid arthritis study

VistaGen partners with Duke University

International phase III trial of MLN-8237 begins

Mayo Clinic receives NIH grant to research use of new peptide to treat heart attacks

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.